FATE THERAPEUTICS INC Earnings Per Share (Basic)
FATE THERAPEUTICS INC (FATE) reported Earnings Per Share (Basic) of -$0.25 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- FATE THERAPEUTICS INC earnings per share, basic for the quarter ending 2026-06-30 was -$0.25.
- FATE THERAPEUTICS INC earnings per share, basic for the quarter ending 2026-03-31 was -$0.26.
- FATE THERAPEUTICS INC earnings per share, basic for the quarter ending 2025-12-31 was -$0.27.
- FATE THERAPEUTICS INC earnings per share, basic for the quarter ending 2025-09-30 was -$0.27.
- FATE THERAPEUTICS INC earnings per share, basic for fiscal 2025 was -$1.15.
- FATE THERAPEUTICS INC earnings per share, basic for fiscal 2024 was -$1.64.
- FATE THERAPEUTICS INC earnings per share, basic for fiscal 2023 was -$1.64.
- FATE THERAPEUTICS INC earnings per share, basic for fiscal 2022 was -$2.91.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.25 10-Q · filed 2026-08-13 | -$0.51 10-Q · filed 2026-08-13 | -$0.78 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.05 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2026-03-31 | -$0.26 10-Q · filed 2026-05-13 | -$0.53 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.80 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.09 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-12-31 | -$0.27 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$0.54 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$0.83 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.15 10-K · filed 2026-02-26 |
| 2025-09-30 | -$0.27 10-Q · filed 2025-11-13 | -$0.56 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.88 10-Q · filed 2025-11-13 | -$1.32 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-06-30 | -$0.29 10-Q · filed 2026-08-13 | -$0.61 10-Q · filed 2026-08-13 | -$1.05 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.45 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-03-31 | -$0.32 10-Q · filed 2026-05-13 | -$0.76 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.16 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.49 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2024-12-31 | -$0.44 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$0.85 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$1.17 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$1.64 10-K · filed 2026-02-26 |
| 2024-09-30 | -$0.40 10-Q · filed 2025-11-13 | -$0.73 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$1.19 10-Q · filed 2025-11-13 | -$1.64 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2024-06-30 | -$0.33 10-Q · filed 2025-08-12 | -$0.79 10-Q · filed 2025-08-12 | -$1.23 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$1.69 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2024-03-31 | -$0.47 10-Q · filed 2025-05-13 | -$0.92 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$1.38 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$1.92 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2023-12-31 | -$0.45 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$0.91 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$1.44 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$1.64 10-K · filed 2025-03-05 |
| 2023-09-30 | -$0.46 10-Q · filed 2024-11-12 | -$0.99 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$1.19 10-Q · filed 2024-11-12 | -$1.77 derived: net income ÷ weighted average shares · filed 2024-11-12 |
| 2023-06-30 | -$0.54 10-Q · filed 2024-08-13 | -$0.73 10-Q · filed 2024-08-13 | -$1.31 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$2.17 derived: net income ÷ weighted average shares · filed 2024-11-12 |
| 2023-03-31 | -$0.19 10-Q · filed 2024-05-09 | -$0.77 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$1.63 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$2.42 derived: net income ÷ weighted average shares · filed 2024-11-12 |
| 2022-12-31 | -$0.58 derived: net income ÷ weighted average shares · filed 2024-02-26 | -$1.44 derived: net income ÷ weighted average shares · filed 2024-02-26 | -$2.23 derived: net income ÷ weighted average shares · filed 2024-02-26 | -$2.91 10-K · filed 2024-02-26 |
| 2022-09-30 | -$0.86 10-Q · filed 2023-11-08 | -$1.65 derived: net income ÷ weighted average shares · filed 2023-11-08 | -$2.33 10-Q · filed 2023-11-08 | -$3.05 derived: net income ÷ weighted average shares · filed 2023-11-08 |
| 2022-06-30 | -$0.79 10-Q · filed 2023-08-08 | -$1.47 10-Q · filed 2023-08-08 | -$2.19 derived: net income ÷ weighted average shares · filed 2023-11-08 | -$2.64 derived: net income ÷ weighted average shares · filed 2023-11-08 |
| 2022-03-31 | -$0.68 10-Q · filed 2023-05-03 | -$1.40 derived: net income ÷ weighted average shares · filed 2023-11-08 | -$1.85 derived: net income ÷ weighted average shares · filed 2023-11-08 | -$2.44 derived: net income ÷ weighted average shares · filed 2023-11-08 |
| 2021-12-31 | -$0.72 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$1.17 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$1.76 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.24 10-K · filed 2023-02-28 |
| 2021-09-30 | -$0.45 10-Q · filed 2022-11-03 | -$1.04 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$1.52 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$0.58 10-Q · filed 2022-08-03 | -$1.07 10-Q · filed 2022-08-03 | ||
| 2020-12-31 | -$2.10 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |